Serelaxin
Also known as: recombinant relaxin-2, RLX030
Recombinant relaxin-2 with vasodilatory and anti-fibrotic properties studied in acute heart failure models.
Quick Reference
Serelaxin - Research Images
PSO vial render · Scientific images from Wikipedia · Tap to enlarge
Overview
Chemical compound
Serelaxin is a medication which is marketed in Russia for the treatment of acute heart failure (AHF), targeting the relaxin receptor. It was also under development in other places in the world, including in the United States, Europe, and Asia, but ultimately was not marketed in these areas.
Mechanism of Action
Serelaxin is a medication which is marketed in Russia for the treatment of acute heart failure (AHF), targeting the relaxin receptor. It was also under development in other places in the world, including in the United States, Europe, and Asia, but ultimately was not marketed in these areas.
What Researchers Are Saying
Community Reports - Not Medical Advice
The following is aggregated from public forums, Reddit, and research communities. These are anecdotal reports from researchers only - not verified clinical data and not a recommendation of any kind.
Serelaxin (also known as recombinant relaxin-2, RLX030) is studied within the peptide research community. Recombinant relaxin-2 with vasodilatory and anti-fibrotic properties studied in acute heart failure models.
Last updated October 28, 2026
Research status: active. Serelaxin appears across peptide research forums and academic literature. Researchers note this compound falls in the other category.
Last updated October 28, 2026
What Do You Think of This Peptide?
Share your opinion or research experience with Serelaxin. Comments are reviewed before appearing.